Meet ApplyKite Twin, the application assistant that learns with you

Meet your Twin, it learns with you

Your Twin learns with you

Launch week codes:30% off annual Pro20% off monthly Pro

Ends in00h00m00s

Elad Sharon

Associate Professor

Harvard University

United States

Research Interests

Explore related searches

Professors in United States Professors in Immunology Immunology professors in United States

Articles (20)

Year:

2026

Year:

2026

Year:

2026

Year:

2026

Year:

2026

Year:

2026

Year:

2026

Year:

2025

Year:

2025

Year:

2025

Year:

2025

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2023

Year:

2023

Year:

2023

Year:

2023

Year:

2023

Collaborators (8)

Ramya Ramaswami

National Cancer Institute

UNITED STATES

View details

Hongtao Liu

University of Wisconsin-Madison

UNITED STATES

View details

Lisa McShane

Associate Director, Division of Cancer Treatment & Diagnosis

National Cancer Institute

UNITED STATES

View details

Dimitrios Tzachanis

Professor of Medicine

University of California, San Diego

UNITED STATES

View details

Robert Gray

Dana-Farber Cancer Institute

UNITED STATES

View details

Maria Farooq

National Cancer Institute

UNITED STATES

View details

Megan Othus

Fred Hutchinson Cancer Research Center

UNITED STATES

View details

Ferdinandos Skoulidis

The University of Texas MD Anderson Cancer Center

UNITED STATES

View details

ApplyKite TwinLearns as you apply

Make your next move.

Prepare your application

Review drafts before you send them.

Elad Sharon

Research Interests

Explore related searches

Articles (20)

Cancer Chemoimmunotherapy: Time Will Tell

Crizotinib in Patients with Tumors with MET Amplification or Exon 14 Deletion: Results from the NCI-MATCH ECOG-ACRIN Trial (EAY131) Subprotocols C1 and C2

Immune Checkpoint Inhibitor–Associated Acute Kidney Injury

The weight of the enemy: Tumor burden as a tumor‐agnostic prognostic marker and the limits of immunotherapy

Addressing Biases in Analysis of Time of Infusion: NCI/SWOG Trial S1404 Among Participants With High-Risk Resectable Melanoma Who Received Adjuvant Anti–PD-1 Therapy

The Landscape of Adolescent and Young Adult (AYA) Survivorship: A Case Report and Narrative Review of Legislation, Research, and Gaps in AYA Survivorship in the US

Atezolizumab for Alveolar Soft Part Sarcoma: A Clinical Trial Update

Cancer Immunotherapy Trials Network 12: Pembrolizumab in HIV-Associated Kaposi Sarcoma

First cycle toxicity and survival in patients with rare cancers treated with checkpoint inhibitors

Demographic Trends in NCI-Sponsored Early-Phase Clinical Trials (2000–2023): A Cohort Study

Randomized phase 2 study to assess the role of single-agent nivolumab to maintain remission in acute myeloid leukemia

SWOG 1609 cohort 48: anti–CTLA‐4 and anti–PD‐1 for advanced gallbladder cancer

Navigating the Complexities of Artificial Intelligence–Enabled Real-World Data Collection for Oncology Pharmacovigilance

Trastuzumab and Pertuzumab in Patients with Non-Breast/Gastroesophageal HER2-Amplified Tumors: Results from the NCI–MATCH ECOG–ACRIN Trial (EAY131) Subprotocol J

A Phase II Basket Trial of Dual Anti–CTLA-4 and Anti–PD-1 Blockade in Rare Tumors (DART SWOG 1609 Cohort 47) in Patients with Gestational Trophoblastic Neoplasia

Signal detection in real‐world data and confirmation in clinical trials: Diabetes as a case study for a conversation worth having

Society for Immunotherapy of Cancer (SITC) checkpoint inhibitor resistance definitions: efforts to harmonize terminology and accelerate immuno-oncology drug development

Design of phase II oncology trials evaluating combinations of experimental agents

The Impact of Improved Treatments on Survival of Adult U.S. Leukemia Patients: 1990–2018

Addressing resistance to PD-1/PD-(L)1 pathway inhibition: considerations for combinatorial clinical trial designs

Collaborators (8)

Ramya Ramaswami

Hongtao Liu

Lisa McShane

Dimitrios Tzachanis

Robert Gray

Maria Farooq

Megan Othus

Ferdinandos Skoulidis

Make your next move.